The advent of gene therapy has unlocked new possibilities for treating diseases previously regarded as intractable. However, producing adeno-associated virus (AAV)-mediated gene therapy products ...
Gene therapy (introducing genetic material into living cells to fix, replace, enhance, or block a faulty gene) is rapidly gaining traction as a strategy for the treatment of genetic diseases. The ...
After decades of research, gene therapy is finally on track to deliver solutions to myriad diseases once considered untreatable. More than 400 gene therapy trials are currently underway in the United ...
Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab ® AAVX Titer ...
Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Download Brochure The need for viral vectors and plasmid DNA ...
MINNEAPOLIS, July 28, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and PROGEN today announced the launch of the Simple Plex™ Adeno-Associated Virus (AAV2) viral titer assay for AAV2 ...
Simple Plex AAV assays combine industry leading AAV antibody reagents from PROGEN with convenience and simplicity of the fully automated Ella platform. MINNEAPOLIS, Oct. 11, 2022 /PRNewswire/ -- ...
Recombinant adeno-associated virus (AAV) and lentiviral vectors (LV) are vehicles for direct delivery of therapeutic genes to patients' cells. In the coming years, the use of AAV and LV in clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results